Comparison of Upfront Haploidentical Hematopoietic Stem Cell Transplantation and Salvage Haploidentical Hematopoietic Stem Cell Transplantation After Immunosuppressive Therapy in Children with Acquired Severe Aplastic Anemia - a Multicenter Study

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 May 9

PMID 38720904

Authors

Danqi Luo

Yuhua Qu

Dao Wang

Benshan Zhang

Ming Sun

Hao Xiong

Jun Lu

Rui Yang

Mingyi Zhao

Haiyan Liu

Hua Jiang

Affiliations

Soon will be listed here.

Abstract

Background: For children with severe aplastic anemia, if the first immunosuppressive therapy (IST) fails, it is not recommended to choose a second IST. Therefore, for patients without matched sibling donor (MSD) and matched unrelated donor (MUD), haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) can be chosen as a salvage treatment. This article aims to explore the comparison between upfront Haplo-HSCT and salvage Haplo-HSCT after IST.

Methods: 29 patients received salvage Haplo-HSCT, and 50 patients received upfront Haplo-HSCT. The two groups received Bu (Busulfan, 3.2mg/kg/d*2d on days -9 to-8), CY (Cyclophosphamide, 60mg/kg/d*2d on days -4 to-3), Flu (fludarabine, 40mg/m/d*5d on days -9 to -5) and rabbit ATG (Anti-thymocyte globulin, total dose 10mg/kg divided into days -4 to -2).

Results: The OS of the salvage Haplo-HSCT group showed no difference to the upfront Haplo-HSCT group (80.2 ± 8.0% vs. 88.7 ± 4.8%, p=0.37). The FFS of the salvage Haplo-HSCT group also showed no difference to the frontline Haplo-HSCT group (75 ± 8.2% vs. 84.9 ± 5.3%, p=0.27). There was no significant difference in the incidence of other complications after transplantation between the two groups, except for thrombotic microangiopathy (TMA). In the grouping analysis by graft source, the incidence of II-IV aGVHD in patients using PBSC ± BM+UCB was lower than that in the PBSC ± BM group (p=0.010).

Conclusion: Upfront Haplo-HSCT and salvage Haplo-HSCT after IST in children with acquired severe aplastic anemia have similar survival outcomes. However, the risk of TMA increases after salvage Haplo-HSCT. This article provides some reference value for the treatment selection of patients. In addition, co-transplantation of umbilical cord blood may reduce the incidence of GVHD.

References

Stein R, Means Jr R, Krantz S, FLEXNER J, Greer J . Treatment of aplastic anemia with an investigational antilymphocyte serum prepared in rabbits. Am J Med Sci. 1994; 308(6):338-43. DOI: 10.1097/00000441-199412000-00005. View

Liu L, Zhang Y, Jiao W, Zhou H, Wang Q, Jin S . Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia. Leukemia. 2020; 34(12):3359-3369. DOI: 10.1038/s41375-020-0933-7. View

Zhang X, Chen J, Han M, Huang H, Jiang E, Jiang M . The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021; 14(1):145. PMC: 8441240. DOI: 10.1186/s13045-021-01159-2. View

Yoshida N, Kojima S . Updated Guidelines for the Treatment of Acquired Aplastic Anemia in Children. Curr Oncol Rep. 2018; 20(9):67. DOI: 10.1007/s11912-018-0716-8. View

Deotare U, Al-Dawsari G, Couban S, Lipton J . G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept. Bone Marrow Transplant. 2015; 50(9):1150-6. DOI: 10.1038/bmt.2015.80. View

Dufour C, Pillon M, Passweg J, Socie G, Bacigalupo A, Franceschetto G . Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014; 99(10):1574-81. PMC: 4181253. DOI: 10.3324/haematol.2014.106096. View

Camitta B, Rappeport J, Parkman R, Nathan D . Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975; 45(3):355-63. View

Yao D, Tian Y, Li J, Li B, Lu J, Ling J . Association between haploidentical hematopoietic stem cell transplantation combined with an umbilical cord blood unit and graft--host disease in pediatric patients with acquired severe aplastic anemia. Ther Adv Hematol. 2022; 13:20406207221134409. PMC: 9619284. DOI: 10.1177/20406207221134409. View

Tichelli A, Passweg J, Nissen C, Bargetzi M, Hoffmann T, Wodnar-Filipowicz A . Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol. 1998; 100(2):393-400. DOI: 10.1046/j.1365-2141.1998.00578.x. View

10.

Liu Z, Zhang Y, Xiao H, Yao Z, Zhang H, Liu Q . Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase II trial results. Bone Marrow Transplant. 2017; 52(5):704-710. DOI: 10.1038/bmt.2016.347. View

11.

Xu Z, Huang X . Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges. Bone Marrow Transplant. 2020; 56(4):779-785. DOI: 10.1038/s41409-020-01169-7. View

12.

Scheinberg P, Nunez O, Young N . Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006; 133(6):622-7. DOI: 10.1111/j.1365-2141.2006.06098.x. View

13.

Xu L, Zhang X, Wang F, Mo X, Han T, Han W . Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia. Bone Marrow Transplant. 2016; 52(3):381-387. DOI: 10.1038/bmt.2016.281. View

14.

Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A . Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano.... Br J Haematol. 1999; 107(2):330-4. DOI: 10.1046/j.1365-2141.1999.01693.x. View

15.

Marsh J, Hows J, Bryett K, Al-Hashimi S, Fairhead S, Gordon-Smith E . Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987; 70(4):1046-52. View

16.

Yang S, Yuan X, Ma R, Jiang L, Guo J, Zang Y . Comparison of Outcomes of Frontline Immunosuppressive Therapy and Frontline Haploidentical Hematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anemia Who Lack an HLA-Matched Sibling Donor. Biol Blood Marrow Transplant. 2019; 25(5):975-980. DOI: 10.1016/j.bbmt.2019.01.017. View

17.

Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T . Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood. 2007; 111(3):1054-9. DOI: 10.1182/blood-2007-08-099168. View

18.

Liu L, Wang X, Jin S, Hao L, Zhang Y, Zhang X . Haploidentical hematopoietic stem cell transplantation for nonresponders to immunosuppressive therapy against acquired severe aplastic anemia. Bone Marrow Transplant. 2015; 51(3):424-7. DOI: 10.1038/bmt.2015.249. View

19.

Yagasaki H, Takahashi Y, Hama A, Kudo K, Nishio N, Muramatsu H . Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia. Bone Marrow Transplant. 2010; 45(10):1508-13. DOI: 10.1038/bmt.2009.378. View

20.

Choi Y, Yi E, Lee J, Sung K, Koo H, Yoo K . Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor. Bone Marrow Transplant. 2016; 52(1):47-52. DOI: 10.1038/bmt.2016.223. View